EC
CORT icon

EntryPoint Capital’s Corcept Therapeutics CORT Stock Holding History

EntryPoint Capital’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-9,757
Closed -$317K – 768
2024
Q2 		$317K Sell
9,757
-4,029
-29% -$110K 0.15% 157
2024
Q1 		$347K Buy
13,786
+4,802
+53% +$113K 0.31% 11
2023
Q4 		$292K Buy
+8,984
New +$247K 0.28% 28

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

EntryPoint Capital's CORT Position: Q3 2024 in Review

EntryPoint Capital sold out of Corcept Therapeutics (CORT) in Q3 2024, closing a stake of 9,757 shares — an estimated $317K sold.

EntryPoint Capital first reported a position in CORT in Q4 2023 and held it in 3 quarters. The position peaked at $347K in Q1 2024. 321 funds tracked by Wall St. Rank hold CORT as of Q3 2024.

  • EntryPoint Capital reported no remaining Corcept Therapeutics position as of Q3 2024 after selling out during the quarter.
  • EntryPoint Capital sold 9,757 Corcept Therapeutics shares in Q3 2024, an estimated $317K.
  • EntryPoint Capital first reported a position in Corcept Therapeutics in Q4 2023 and held it in 3 quarters.
  • EntryPoint Capital's Corcept Therapeutics position peaked at $347K in Q1 2024.
  • 321 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2024.

Based on EntryPoint Capital's 13F filing for Q3 2024, filed 13 Nov 2024.